HENLIUS(02696): HLX3901 injection (DLL3xDLL3xCD3xCD28 tetra-specific antibody) clinical trial application for late-stage/metastatic solid tumor patients approved by the National Medical Products Administration.
Fuhong Hanlin (02696) announced recently that the Phase 1 clinical trial application (IND) of HLX3901 injection (DLL3xDLL3xCD3xCD28 tetra-specific antibody) in late-stage/metastatic solid tumor patients has been approved by the National Medical Products Administration (NMPA).
HENLIUS (02696) announced that recently, the 1st phase clinical trial application (IND) of HLX3901 injection (DLL3xDLL3xCD3xCD28 tetra-specific antibody) in patients with advanced/metastatic solid tumors has been approved by the National Medical Products Administration (NMPA).
Related Articles
On March 9, MNSO(09896) spent 1.73 million Hong Kong dollars to repurchase 52,600 shares.
Shenwan Hongyuan Group (06806): "23th C2 application" will be redeemed and delisted on March 6th.
On March 9, Le Saunda (00738) spent HK$58,000 to repurchase 200,000 shares.
On March 9, MNSO(09896) spent 1.73 million Hong Kong dollars to repurchase 52,600 shares.
Shenwan Hongyuan Group (06806): "23th C2 application" will be redeemed and delisted on March 6th.
On March 9, Le Saunda (00738) spent HK$58,000 to repurchase 200,000 shares.
RECOMMEND
